Overview
Fei Xu practices in Xi'an, China. Xu is rated as a Distinguished expert by MediFind in the treatment of Conversion Disorder. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Conversion Disorder, Microvascular Decompression, and Spinal Fusion.
Their clinical research consists of co-authoring 1930 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles in the study of Conversion Disorder.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Conversion DisorderXu isDistinguished. Learn about Conversion Disorder.
- Lung CancerXu isDistinguished. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Advanced
- Adenoid Cystic Carcinoma
- AsthmaXu isAdvanced. Learn about Asthma.
- AtherosclerosisXu isAdvanced. Learn about Atherosclerosis.
- B-Cell LymphomaXu isAdvanced. Learn about B-Cell Lymphoma.
- Breast CancerXu isAdvanced. Learn about Breast Cancer.
- Cerebral HypoxiaXu isAdvanced. Learn about Cerebral Hypoxia.
- Experienced
- Abdominal Aortic Aneurysm (AAA)
- Abdominal Obesity Metabolic Syndrome
- Acute Interstitial Pneumonia
- Acute Lymphoblastic Leukemia (ALL)
- Acute Mountain SicknessXu isExperienced. Learn about Acute Mountain Sickness.
- Acute Myeloid Leukemia (AML)